biomarker discovery News
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis.
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...
-
Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...
By CD Genomics
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
-
Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP. Analysis of blood samples from CAMP, the largest study yet ...
By NeuroPointDX
-
SomaGenics strengthens its IP and technology position in small RNA analysis and biomarker discovery with new patent and publication
Santa Cruz, CA, September 2018 - SomaGenics announced today the issue of US Patent 10,041,107, a continuation of SomaGenics’ patent family entitled “Methods and Compositions for Detection of small RNAs.” The new patent broads protection for SomaGenics’ innovative, circularization-based approaches to accurately detect and quantify small RNAs, including key ...
-
MOBILion Systems Inc. Announces $60 Million Series C Financing Round Led by D1 Capital Partners to Expand Commercial Activities and Accelerate Product Development
MOBILion Systems Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. The round was led by D1 Capital Partners with the remaining funds contributed by existing investors aMoon, Agilent Technologies (NYSE:A), IP Group, Hostplus and ...
-
Official Opening of Service Laboratory
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. This will enable the Research & Development departments worldwide to access their Precision Microbiome Profiling (PMP™) platform. The service laboratory is located at the Oslo’s Science Park’s premier lab sharing facility, the ShareLab. The lab ...
By Bio-Me
-
PERKINELMER LAUNCHES BIOXPRESSION™ BIOMARKER PLATFORM AT THE ASMS CONFERENCE ON MASS SPECTROMETRY
Untitled Document Biomarker Platform Provides a Complete Solution for Disease Biomarker Discovery and Screening SAN ANTONIO, Texas – PerkinElmer Inc. (NYSE: PKI ), a leading provider in genetic screening, drug discovery, life science research, and analytical solutions, today announced the launch of its BioXPRESSION™ Biomarker discovery and screening platform at the 53rd ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
PeakInvestigator™ v1.3 Mass Spec Deconvolution & Centroiding Software Released, Improving Biomarker Discovery Rates
Veritomyx, Inc.. a leading innovator in mass spectral analysis software, today announced the release of Peaklnvestigator™ v1.3 software services ("Peaklnvestigator*), applying advanced signal processing algorithms to reveal peaks and biomarkers previously hidden within overlaps or below analysis thresholds in raw mass spectral data. The resulting more complete and precise peak lists ...
-
CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. The company has optimized its Cancer Hotspot Panel Sequencing service to meet the most challenging research process. Cancer is ...
By CD Genomics
-
Aurora BioPharma To Join In On A Presentation And Discussion On The GBM AGILE Trial At The Ritz-Carlton, Pentagon City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th. About ...
-
Thermo Fisher Scientific Announces Collaborations to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization
Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating ...
-
NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectrum disorder (ASD) at the National TACA Autism Conference. CAMP is the largest clinical study ...
By NeuroPointDX
-
CD Genomics Introduces Advanced Exosomal RNA Sequencing Service for Enhanced Molecular Insights
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. This innovative service is set to provide researchers with comprehensive and accurate analysis of exosomal RNA, facilitating a deeper understanding of their functional significance in various biological processes. Exosomes, small extracellular ...
By CD Genomics
-
The MALDI-Imaging Lipidomics Service Is Now Available Through Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The company has recently announced the fully-developed MALDI-Imaging Lipidomics Service to research the distribution of lipids in tissues. Lipidomics MALDI imaging mass ...
-
MicrobioSeq Releases SMRT-Based Transcriptomics Analysis Service to Boost Your Discovery
MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable sequencing, genotyping, microarray, and bioinformatics services. Nowadays, the company announced SMRT-based transcriptomics analysis, which is useful to identify novel transcript isoforms, fusion gene ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you